首页> 美国卫生研究院文献>Aging (Albany NY) >TMEM106C contributes to the malignant characteristics and poor prognosis of hepatocellular carcinoma
【2h】

TMEM106C contributes to the malignant characteristics and poor prognosis of hepatocellular carcinoma

机译:TME106C有助于恶性特征和肝细胞癌的预后不良

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Transmembrane protein (TMEM) is a kind of integral membrane protein that spans biological membranes. The functions of most members of the TMEM family are unknown. Here, we conducted bioinformatic analysis and biological validation to investigate the role of TMEM106C in HCC. First, GEPIA and OncomineTM were used to analyze TMEM106C expression, which was verified by real-time PCR and western blot analyses. Then, the biological functions of TMEM106C were explored by CCK8 and transwell assays. The prognostic value of TMEM106C was analyzed by UALCAN. LinkedOmics was used to analyze TMEM106C pathways generated by Gene Ontology. A protein-protein interaction network (PPI) was constructed by GeneMANIA. We demonstrated that TMEM106C was overexpressed in HCC and that inhibition of TMEM106C significantly suppressed the proliferation and metastasis of HCC through targeting CENPM and DLC-1. Upregulation of TMEM106C was closely correlated with sex, tumor stage, tumor grade and prognosis. Overexpression of TMEM106C was linked to functional networks involving organelle fission and cell cycle signaling pathways through the regulation of CDK kinases, E2F1 transcription factors and miRNAs. Our data demonstrated that TMEM106C contributes to malignant characteristics and poor prognosis in HCC, which may serve as a prognostic biomarker and potential therapeutic target.
机译:跨膜蛋白(TMEM)是一种跨越生物膜的整体膜蛋白。 TMEM系列大多数成员的功能都是未知的。在这里,我们进行了生物信息分析和生物验证,以研究TMEM106C在HCC中的作用。首先,使用Gepia和Oncominetm来分析TMEM106C表达,通过实时PCR和Western印迹分析来验证。然后,CCK8和Transwell测定探索了TMEM106C的生物学功能。通过Ualcan分析TMEM106C的预后值。 LinkedOmics用于分析由基因本体产生的TMEM106C途径。由Genemania构建蛋白质 - 蛋白质相互作用网络(PPI)。我们证明,TME106C在HCC中过表达,TME106C的抑制通过靶向CENPM和DLC-1显着抑制了HCC的增殖和转移。 TME106C的上调与性别,肿瘤阶段,肿瘤等级和预后密切相关。 TME106C的过表达通过调节CDK激酶,E2F1转录因子和miRNA来连接TME106C的功能网络与涉及细胞器裂变和细胞周期信号传导途径的功能网络连接。我们的数据表明,TME106C有助于恶性特征和HCC预后差,其可以作为预后生物标志物和潜在的治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号